Europe Cardiovascular Therapeutic Drugs Market by disease (Arteriosclerosis, Cardiac arrhythmias, Myocardial infarction, acute coronary syndrome, Peripheral artery disease, Coronary artery disease, hypertension, hyperlipidaemia, thrombosis, cardiac failure diseases and other cardiovascular diseases), by drug class (monotherapies and combination) and by Region – Industry Analysis, Size, Share, Growth, Trends, and Forecast (2016 – 2021)

Europe Cardiovascular Therapeutic Drugs Market by disease (Arteriosclerosis, Cardiac arrhythmias, Myocardial infarction, acute coronary syndrome, Peripheral artery disease, Coronary artery disease, hypertension, hyperlipidaemia, thrombosis, cardiac failure diseases and other cardiovascular diseases), by drug class (monotherapies and combination) and by Region – Industry Analysis, Size, Share, Growth, Trends, and Forecast (2016 – 2021)

ID: 1428 | Pages: 131 | November 2016 | Region: Europe


Europe Cardiovascular Therapeutic Drugs Market is worth USD 29.16 billion in 2016 and is estimated to grow at a CAGR of 2.05% reaching a value of USD 32.28 billion by 2021. There has been an increased usage of drug therapies with rising prevalence of cardiovascular diseases and evolvement of highly effective therapies helping the market for cardiovascular therapeutic drugs to grow.

Cardiovascular therapeutics drugs refers to the prescribed medicines and drugs for the diseases which are related to the functioning and treatment of heart and blood vessels. While cardiovascular diseases remains to be the leading cause of dead, the major reason causing cardiovascular problems include heart failure, blood clots, coronary artery diseases, high cholesterol and others.

The market is driven by a host of factors which includes rise in aging population, rise in per capita spending on healthcare and epidemic of general medical issues like obesity and diabetes. With cardiovascular disorders being the most common cause for morbidity and mortality, the market has a tremendous value and continue to do so in the coming years. However, there are a few restraints the market likes to overcome which includes rising costs for drug development and lowering of target population. And also, despite of high prevalence, drug development pipelines for cardiovascular disorders has been stagnant for a variety of reasons.

Europe cardiovascular therapeutic drugs market is divided on the basis of type of disease and drug class. The various diseases relating to the cardiovascular diseases includes thrombosis, Arteriosclerosis, Myocardial infarction, Cardiac arrhythmias, Peripheral artery disease, acute coronary syndrome, Coronary artery disease, hyperlipidaemia, hypertension, cardiac failure diseases and other cardiovascular diseases. On the basis of drug class, the market is further categorised into combination drug classes and monotherapies. Europe’s market is geographically segmented into United Kingdom, France, Germany, Italy and Spain.

The companies leading the cardiovascular therapeutic drugs market include Bristol-Myers Squibb (BMS), Novartis, AstraZeneca, Pfizer, Merck, Sanofi, Bayer, boehringer ingelheim, Takeda and Johnson & Johnson.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Disease                  

                                5.1.1 Arteriosclerosis     

                                5.1.2 Cardiac arrhythmias            

                                5.1.3 Myocardial infarction         

                                5.1.4 Acute Coronary Syndrome

                                5.1.5 Peripheral artery disease  

                                5.1.6 Coronary artery disease    

                                5.1.7 Hypertension        

                                5.1.8 Hyperlipidaemia   

                                5.1.9 Thrombosis            

                                5.1.10 Cardiac failure diseases  

                                5.1.11 Others   

                5.2 By Drug Class                             

                                5.2.1 Monotherapies     

                                5.2.2 Combination Therapies     

6. Geographical Analysis                                              

                6.1 Introduction                              

                6.2 U.K                

                6.3 Spain                             

                6.2.4 Germany                 

                6.2.5 Italy                           

                6.2.6 France                      

7. Pipeline Product Analysis                                        

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                     

                7.3 Molecular Targets in the Pipeline                                     

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                 

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.               

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9. Market Leaders' Analysis                                        

                9.1 AstraZeneca               

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Strategic Evaluation and Operations            

                                9.1.4 Financial analysis  

                                9.1.5 Legal issues            

                                9.1.6 Recent Developments       

                                9.1.7 SWOT analysis       

                                9.1.8 Analyst View          

                9.2 Novartis                       

                9.3 Bristol-Myers Squibb                              

                9.4 Pfizer                            

                9.5 Sanofi                           

                9.6 Merck                           

                9.7 Bayer                            

                9.8 Takeda                         

                9.9 Boehringer Ingelheim                            

                9.10 Johnson & Johnson                              

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11. Expert Opinions                                        

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Europe Cardiovascular Therapeutic Drugs Market By Region, From 2016-2020 (USD Million)                                                          
  2. Europe Cardiovascular Therapeutic Drugs Market By Disease, From 2016-2020 (USD Million)                                                        
  3. Europe Arteriosclerosis Market By Region, From 2016-2020 (USD Million)                                                              
  4. Europe Cardiac arrhythmias Market By Region, From 2016-2020 (USD Million)                                                     
  5. Europe Myocardial infarction Market By Region, From 2016-2020 (USD Million)                                                  
  6. Europe Acute Coronary Syndrome Market By Region, From 2016-2020 (USD Million)                                                        
  7. Europe Peripheral artery disease Market By Region, From 2016-2020 (USD Million)                                                           
  8. Europe Coronary artery disease Market By Region, From 2016-2020 (USD Million)                                                             
  9. Europe Hypertension Market By Region, From 2016-2020 (USD Million)                                                  
  10. Europe Hyperlipidaemia Market By Region, From 2016-2020 (USD Million)                                                            
  11. Europe Thrombosis Market By Region, From 2016-2020 (USD Million)                                                     
  12. Europe Cardiac failure diseases Market By Region, From 2016-2020 (USD Million)                                                              
  13. Europe Cardiovascular Therapeutic Drugs Market By Drug Class, From 2016-2020 (USD Million)                                                   
  14. Europe Monotherapies Market By Region, From 2016-2020 (USD Million)                                                              
  15. Europe Combination Therapies Market By Region, From 2016-2020 (USD Million)                                                              
  16. U.K Cardiovascular Therapeutic Drugs Market By Disease, From 2016-2020 (USD Million)                                               
  17. U.K Cardiovascular Therapeutic Drugs Market By Drug Class, From 2016-2020 (USD Million)                                                          
  18. Spain Cardiovascular Therapeutic Drugs Market By Disease, From 2016-2020 (USD Million)                                                            
  19. Spain Cardiovascular Therapeutic Drugs Market By Drug Class, From 2016-2020 (USD Million)                                                      
  20. Germany Cardiovascular Therapeutic Drugs Market By Disease, From 2016-2020 (USD Million)                                                    
  21. Germany Cardiovascular Therapeutic Drugs Market By Drug Class, From 2016-2020 (USD Million)                                                               
  22. Italy  Cardiovascular Therapeutic Drugs Market By Disease, From 2016-2020 (USD Million)                                                             
  23. Italy  Cardiovascular Therapeutic Drugs Market By Drug Class, From 2016-2020 (USD Million)                                                       
  24. France Cardiovascular Therapeutic Drugs Market By Disease, From 2016-2020 (USD Million)                                                         
  25. France Cardiovascular Therapeutic Drugs Market By Drug Class, From 2016-2020 (USD Million)                                                    

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
502, Kakatiya's Empire,
Jubilee Gardens, Hyderabad,
Telangana, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2017 Market Data Forecast
All Rights Reserved.